[1] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 实用肝脏病杂志,2007,10(1):1-3. [2] 中华医学会消化病学分会肝胆疾病协作组. 药物性肝损伤诊治建议(草案). 中华消化杂志,2007,27(11):765-767. [3] 中华医学会风湿病学分会. 自身免疫性肝病诊断和治疗指南. 中华风湿病学杂志,2011,15(8):556-558. [4] 病毒性肝炎防治方案. 中华传染病杂志,2001,15(1):55-61. [5] Nigam SK. What do drug transporters really do Nat Rev Drug Discov,2015,14(1):29-44. [6] Than NN,Newsome PN.A concise review of non-alcoholic fatty liver disease. Atherosclerosis,2015,239(1):192-202. [7] Sanchez-Torrijos Y,Ampuero J,Romero-Gómez M.Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients:What we do,what we should do. World J Hepatol,2017,9(15):697-703. [8] 管军,徐烨. 青少年非酒精性脂肪肝相关危险因素分析. 实用肝脏病杂志,2017,20(3):347-349. [9] Issa D,Wattacheril J,Sanyal AJ.Treatment options for nonalcoholic steatohepatitis-a safety evaluation. Expert Opin Drug Saf,2017,16(8):903-913. [10] Katarey D,Verma S.Drug-induced liver injury. Clin Med,2016,16(Suppl 6):s104. [11] Fan JG,Farrell G C.Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol,2009,50(1):204-210. [12] Wang F,Fan J,Zhang Z,et al.The global burden of liver disease:The major impact of China. Hepatology,2015,60(6):2099-2108. [13] Byrne CD,Targher G.NAFLD:a multisystem disease. J Hepatol,2015,62(1):S47-S64. [14] Abd ElKader SM,ElDen Ashmawy EM. Non-alcoholic fatty liver disease:The diagnosis and management. World J Hepatol,2015,7(6):846. [15] Nascimbeni F,Pais R,Bellentani S,et al.From NAFLD in clinical practice to answers from guidelines. J Hepatol,2013,59(4):859-871. [16] Kim J,Eisenberg D,Azagury D,et al.American Society for Metabolic and Bariatric Surgery position statement on long-term survival benefit after metabolic and bariatric surgery. Surg Obes Relat Dis,2016,12(3):453-459. [17] Melissas J,Stavroulakis K,Tzikoulis V,et al.Sleeve gastrectomy vs Roux-en-Y gastric bypass. Data from IFSO-European Chapter Center of Excellence Program. Obes Surg,2016,27(4):1-9. [18] Petriz BA,Castro AP,Almeida JA,et al.Exercise induction of gut microbiota modifications in obese,non-obese and hypertensive rats. BMC Genomics,2014,15:511. [19] Clarke SF,Murphy EF,O'Sullivan O,et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut,2014,63(12):1913-1920. [20] Bjornsson ES.Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis,2014,34(2):115-122. [21] Conforti A,Leone R,Ghiotto E,et al.Spontaneous reporting of drug-related hepatic reactions from two Italian regions (lombardy and veneto). Dig Liver Dis,2000,32(8):716-723. [22] de Boer YS,Kosinski AS,Urban TJ,et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol,2017,15(1):103. |